Claim 55% Off TipRanks
- Unlock hedge fund-level data and powerful investing tools for smarter, sharper decisions
- Discover top-performing stock ideas and upgrade to a portfolio of market leaders with Smart Investor Picks
ADICON Holdings Limited ( (HK:9860) ) has issued an update.
ADICON Holdings Limited reported that 2025 was a transitional year for the independent clinical laboratory sector, with its revenue falling 9.5% year on year to RMB 2.64 billion and profit for the year dropping to RMB 22.7 million, though management noted that the pace of decline narrowed each quarter. The group highlighted operational resilience and strong performance in core segments, particularly its co-construction business, which grew revenue by 19.8% and added 69 new projects, deepening partnerships with leading hospitals and regional platforms to build automated, standardized laboratories and reinforcing its competitive position ahead of an anticipated industry recovery in 2026.
The most recent analyst rating on (HK:9860) stock is a Buy with a HK$8.60 price target. To see the full list of analyst forecasts on ADICON Holdings Limited stock, see the HK:9860 Stock Forecast page.
More about ADICON Holdings Limited
ADICON Holdings Limited is a mainland China-based independent clinical laboratory (ICL) service provider, operating testing centers and co-constructed laboratories with hospitals and regional medical platforms. The group focuses on laboratory diagnostics, automation solutions, and standardized testing management to support medical institutions and enhance the quality and efficiency of clinical testing nationwide.
Average Trading Volume: 3,525,515
Technical Sentiment Signal: Sell
Current Market Cap: HK$2.82B
Learn more about 9860 stock on TipRanks’ Stock Analysis page.